Karyopharm Therapeutics (NASDAQ:KPTI) Issues Earnings Results

Karyopharm Therapeutics (NASDAQ:KPTI) released its quarterly earnings data on Thursday. The company reported ($2.23) earnings per share for the quarter, beating the consensus estimate of ($2.26) by $0.03, Zacks reports. The company had revenue of $34.08 million during the quarter, compared to the consensus estimate of $33.16 million.

Here are the key takeaways from Karyopharm Therapeutics’ conference call:

• Phase 3 myelofibrosis readout in March 2026: Karyopharm expects top-line data from its frontline selinexor + ruxolitinib (CENTURY/SENTRI) trial next month, positioning the combo to be the first frontline combination and a potential major value driver if positive.
• Phase 3 endometrial cancer data mid?2026: The EXPORT?EC042 trial remains on track for mid?2026 top?line results, supported by promising long?term SIENNA subgroup data in P53 wild?type/pMMR patients that Karyopharm highlights as a meaningful expansion opportunity.
• Near?term cash runway into Q2 2026: The company ended 2025 with ~$64.1M in cash and says existing liquidity funds operations only into the second quarter, and it is actively evaluating financing and strategic options to bridge to and beyond upcoming readouts.
• Commercial performance and 2026 guidance: Xpovio net product revenue grew to $114.9M in 2025, management expects $115M–$130M in 2026 and continues to position Xpovio in community and peri?T?cell engager settings as a durable commercial foundation.

Karyopharm Therapeutics Price Performance

Shares of Karyopharm Therapeutics stock opened at $8.58 on Friday. The firm has a market cap of $157.10 million, a P/E ratio of -0.52 and a beta of 0.21. The firm has a 50 day simple moving average of $6.98 and a 200 day simple moving average of $6.23. Karyopharm Therapeutics has a fifty-two week low of $3.51 and a fifty-two week high of $10.38.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the company. Geode Capital Management LLC raised its position in shares of Karyopharm Therapeutics by 101.2% during the fourth quarter. Geode Capital Management LLC now owns 187,734 shares of the company’s stock worth $1,382,000 after acquiring an additional 94,445 shares during the last quarter. Bank of America Corp DE increased its position in Karyopharm Therapeutics by 26.8% in the second quarter. Bank of America Corp DE now owns 168,534 shares of the company’s stock worth $726,000 after purchasing an additional 35,626 shares during the period. Walleye Capital LLC bought a new stake in Karyopharm Therapeutics during the 4th quarter worth about $704,000. State Street Corp lifted its position in Karyopharm Therapeutics by 27.2% during the 4th quarter. State Street Corp now owns 58,942 shares of the company’s stock valued at $434,000 after purchasing an additional 12,600 shares during the period. Finally, Bridgeway Capital Management LLC bought a new position in shares of Karyopharm Therapeutics in the 2nd quarter valued at about $163,000. 66.44% of the stock is currently owned by institutional investors.

Karyopharm Therapeutics News Roundup

Here are the key news stories impacting Karyopharm Therapeutics this week:

• Positive Sentiment: Q4 results slightly beat estimates — GAAP loss per share was ($2.23) vs. consensus ($2.26), and revenue of $34.08M topped estimates ($33.16M). The beat reduces downside from the report itself. Karyopharm Therapeutics (KPTI) Reports Q4 Loss, Tops Revenue Estimates
• Positive Sentiment: Near?term clinical catalysts: top?line Phase 3 SENTRY data in myelofibrosis expected in March 2026 and Phase 3 XPORT?EC?042 endometrial cancer readout mid?2026 — binary outcomes that could drive material upside if positive. Karyopharm Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Company Progress
• Neutral Sentiment: Earnings-call materials and full transcripts are available for review — useful for gauging management tone on commercialization and trial timelines but not immediate price movers by themselves. Karyopharm (KPTI) Q4 2025 Earnings Call Transcript
• Neutral Sentiment: Reported large increases in short interest appear to be data errors (entries show 0 shares / NaN). Short?interest figures are unreliable at present and should be rechecked before drawing conclusions.
• Negative Sentiment: Full?year 2026 revenue guidance of $130M–$150M (U.S. XPOVIO net product revenue guidance $115M–$130M) is cautious versus the published consensus (~$145.3M), leaving the midpoint below consensus and prompting investor concern about growth trajectory. Karyopharm Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Company Progress

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on KPTI. Royal Bank Of Canada lowered their price target on Karyopharm Therapeutics from $30.00 to $19.00 and set an “outperform” rating on the stock in a research report on Tuesday, November 4th. Weiss Ratings restated a “sell (d-)” rating on shares of Karyopharm Therapeutics in a research note on Monday, December 29th. Cantor Fitzgerald began coverage on shares of Karyopharm Therapeutics in a research report on Thursday, February 5th. They set an “overweight” rating for the company. The Goldman Sachs Group set a $12.00 price target on shares of Karyopharm Therapeutics in a report on Wednesday, December 17th. Finally, Wall Street Zen raised shares of Karyopharm Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Saturday, November 8th. Six analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $14.83.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics (NASDAQ: KPTI) is a clinical-stage biopharmaceutical company focused on discovering and developing novel first-in-class drugs that target the nuclear export protein XPO1. The company’s lead product, selinexor (marketed as XPOVIO), is an oral selective inhibitor of nuclear export (SINE) compound approved for treatment of multiple myeloma and diffuse large B-cell lymphoma. In addition to selinexor, Karyopharm’s pipeline includes second-generation SINE compounds and combination studies in solid tumors and hematologic malignancies.

Founded in 2008 and headquartered in Newton, Massachusetts, Karyopharm has built a research platform around modulation of nuclear export pathways.